Ocular Epithelium Tight Junction Permeability Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular pathologies, such as allergic conjunctivitis and dry eye syndrome, fail to effectively regulate paracellular permeability of the ocular surface epithelium, leading to increased penetration of allergens and pathogens, and are often associated with side effects from preservatives like benzalkonium chloride.
Innovation Solution
The use of compounds that modulate cytoskeletal tension in ocular epithelial cells to control the opening and closing of tight junctions, thereby regulating paracellular permeability without de novo protein synthesis or structural degradation, using inhibitors like ML-7 to inhibit myosin light chain kinase and other molecules that affect cytoskeletal contraction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for ocular pathologies, then treatment of allergic conjunctivitis and dry eye syndrome is provided, but paracellular permeability of the ocular surface epithelium is not effectively regulated, leading to increased penetration of allergens and pathogens
Solution Approach 1:
The invention changes the physiological parameter of cytoskeletal tension in ocular epithelial cells by administering compounds that modulate this tension. This parameter change directly regulates tight junction permeability, thereby controlling paracellular permeability and preventing allergen and pathogen penetration while treating ocular pathologies.
Solution Approach 2:
The treatment leverages the body's own cytoskeletal mechanisms to regulate tight junctions. By modulating cytoskeletal tension through administered compounds, the ocular epithelium's natural barrier function is enhanced without requiring external structural modifications or de novo protein synthesis, allowing the system to self-regulate its permeability.
2Ease of operation
If compounds modulating cytoskeletal tension are used to regulate tight junctions, then specific and reversible control of paracellular permeability is achieved, but complexity of the treatment mechanism increases
Solution Approach 1:
The invention replaces complex structural modifications or de novo protein synthesis mechanisms with a simpler chemical approach. By using compounds that modulate cytoskeletal tension, the treatment achieves control of tight junction permeability through biochemical modulation rather than mechanical or genetic intervention, simplifying the overall treatment mechanism.
Solution Approach 2:
The treatment acts on the cytoskeletal tension before pathological changes occur or at the onset of disease. By modulating cytoskeletal tension in advance, the tight junctions are pre-conditioned to maintain appropriate permeability, preventing allergen and pathogen penetration before they can cause damage.
3Stability of the object's composition
If preservatives like benzalkonium chloride are used in current treatments, then stability of the treatment solution is improved, but side effects and disruption of the ocular barrier occur
Solution Approach 1:
The invention extracts and removes the harmful preservative component (benzalkonium chloride) from the treatment formulation. By eliminating this preservative and relying instead on compounds that modulate cytoskeletal tension, the treatment maintains solution stability without causing side effects or disrupting the ocular barrier.
Solution Approach 2:
The invention converts the need for preservative stability into a benefit by using alternative compounds that modulate cytoskeletal tension. These compounds not only provide the necessary treatment effect but also inherently maintain solution stability without the harmful side effects associated with traditional preservatives, turning a potential harm into a beneficial property.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a specific, fine, and reversible regulation of ocular surface epithelial permeability, reducing inflammation and preventing the penetration of allergens and pathogens, effectively managing ocular surface disorders and dry eye syndrome.
Implementation Method 1
The compositions and methods of the invention are based in particular on the use of agents or conditions modulating cytoskeletal tension of the epithelial cells of the conjunctiva and cornea
Implementation Method 2
using inhibitors like ML-7 to inhibit myosin light chain kinase and other molecules that affect cytoskeletal contraction
Implementation Method 3
absorption of large molecules and the passage of antigens and/or toxins occur principally by the paracellular route, at the level of 'tight junctions' located between epithelial cells
Implementation Method 4
Epithelial tight junctions (TJ) are structures which link the cells lining mucosal epithelia. These flexible structures, attached to the cytoskeletal components composed of actin and myosin filaments
Data Source
AI summary
The invention concerns compositions and methods for treating and/or preventing ocular pathologies. The invention also concerns compositions and methods enabling the regulation of paracellular permeability of the ocular epithelium. The compositions and methods of the invention are based in particular on the use of agents or conditions modulating the opening of tight junctions of the ocular epithelium. The invention can be used for preventive or curative treatment of various pathologies, such as pathologies of the ocular surface in mammals, particularly in human beings.